• DOI:10.1001/JAMA.1997.03540480062040
• Corpus ID: 1878182

Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel.

@article{Carpenter1998AntiretroviralTF,
  title={Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel.},
  author={Charles C. J. Carpenter and Margaret A. Fischl and Scott M. Hammer and Martin S. Hirsch and Donna M. Jacobsen and David A. Katzenstein and Julio S. G. Montaner and Douglas D. Richman and Michael S. Saag and Robert T. Schooley and Melanie Ann Thompson and Stefano Vella and Patrick G Yeni and Paul A. Volberding},
  journal={JAMA},
  year={1998},
  volume={280 1},
  pages={
          78-86
        }
}

• C. Carpenter, M. Fischl, +11 authors P. Volberding
• Published 25 June 1997
• Medicine
• JAMA

OBJECTIVE
To provide recommendations for antiretroviral therapy based on information available in mid-1998.

PARTICIPANTS
An international panel of physicians with expertise in antiretroviral research and care of patients with human immunodeficiency virus (HIV) infection, first convened by the International AIDS Society-USA in December 1995.

EVIDENCE
The panel reviewed available clinical and basic science study results (including phase 3 controlled trials; clinical, virologic, and immunologic end point data; data presented at research conferences; and studies of HIV pathophysiology); opinions of panel members were also considered. Recommendations were limited to drugs available in mid-1998.

CONSENSUS PROCESS
Panel members monitor new clinical research reports and interim results. The full panel meets regularly to discuss how the new information may change treatment recommendations. Updated recommendations are developed through consensus of the entire panel at each stage of development.

CONCLUSIONS
Accumulating data from clinical and pathogenesis studies continue to support early institution of potent antiretroviral therapy in patients with HIV infection. A variety of combination regimens show potency, expanding choices for initial regimens for individual patients. Plasma HIV RNA assays with increased sensitivity are important in monitoring therapeutic response; however, more data are needed to determine precisely the HIV RNA levels that define treatment failure. Long-term adverse drug effects are beginning to emerge, requiring ongoing attention. Some issues regarding optimal long-term approaches to antiretroviral management are unresolved. The increased complexity in HIV management requires ongoing monitoring of new data for optimal treatment of HIV infection.